Incyte scraps Jakafi combination trials

12 February 2016

US biotech firm Incyte (Nasdaq: INCY) has scrapped Phase III studies assessing the combination of its best-selling cancer drug Jakafi (ruxolitinib) alongside Roche’s (ROG: SIX)) Xeloda (capecitabine).

The trials were terminated when a planned interim analysis failed to reveal a sufficient level of efficacy to warrant continuation.

Ongoing trials of Jakafi in solid tumors are to be discontinued as a result of the findings and Incyte is also ending a dose-finding study of the experimental JAK1 inhibitor INCB39110 in the first-line treatment of metastatic pancreatic cancer.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK